Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.79)
# 97
Out of 5,106 analysts
26
Total ratings
77.27%
Success rate
30.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Assumes: Overweight | $9 | $2.55 | +252.94% | 1 | Nov 18, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $9.63 | +169.99% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $104.94 | +21.97% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $18.12 | +15.89% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $14.12 | +197.45% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $80.27 | -6.57% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $23.40 | +53.85% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $40.05 | +37.33% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $8.53 | +28.96% | 1 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $17.57 | +104.89% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.98 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.34 | +84.33% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.60 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $65.51 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $22.85 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.82 | - | 1 | Oct 31, 2022 |
Black Diamond Therapeutics
Nov 18, 2025
Assumes: Overweight
Price Target: $9
Current: $2.55
Upside: +252.94%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $9.63
Upside: +169.99%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $104.94
Upside: +21.97%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $18.12
Upside: +15.89%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $14.12
Upside: +197.45%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $80.27
Upside: -6.57%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $23.40
Upside: +53.85%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $40.05
Upside: +37.33%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $8.53
Upside: +28.96%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $17.57
Upside: +104.89%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.98
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.34
Upside: +84.33%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $65.51
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $22.85
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.82
Upside: -